TY - JOUR
T1 - Hepatocellular Carcinoma: The Role of Interventional Oncology
AU - DONADON, Matteo Davide
AU - Solbiati, L
AU - Dawson, L
AU - Barry, A
AU - Sapisochin, G
AU - PD, Greig
AU - Shiina, S
AU - Fontana, A
AU - Torzilli, G.
PY - 2016
Y1 - 2016
N2 - BACKGROUND:
Hepatocellular carcinoma (HCC) remains a major health issue because of its increasing incidence and because of the complexity of its management. In addition to the traditional potentially curative treatments, i.e., liver transplantation and surgical resection, other new and emerging local therapies have been applied with promising results.
SUMMARY:
Radiotherapy (RT) and interstitial treatments, such as radiofrequency ablation (RFA), microwave ablation (MWA), and irreversible electroporation (IRE), have recently opened new and interesting treatment scenarios for HCC and are associated with promising results in selected patients. Herein, we describe the emerging role of interventional oncology for the treatment of HCC and focus on the different Western and Eastern approaches.
KEY MESSAGES:
Modern RT and modern interstitial therapies, such as RFA, MWA, and IRE, should be considered for inclusion in HCC therapy guidelines.
AB - BACKGROUND:
Hepatocellular carcinoma (HCC) remains a major health issue because of its increasing incidence and because of the complexity of its management. In addition to the traditional potentially curative treatments, i.e., liver transplantation and surgical resection, other new and emerging local therapies have been applied with promising results.
SUMMARY:
Radiotherapy (RT) and interstitial treatments, such as radiofrequency ablation (RFA), microwave ablation (MWA), and irreversible electroporation (IRE), have recently opened new and interesting treatment scenarios for HCC and are associated with promising results in selected patients. Herein, we describe the emerging role of interventional oncology for the treatment of HCC and focus on the different Western and Eastern approaches.
KEY MESSAGES:
Modern RT and modern interstitial therapies, such as RFA, MWA, and IRE, should be considered for inclusion in HCC therapy guidelines.
UR - https://iris.uniupo.it/handle/11579/199170
U2 - 10.1159/000449346
DO - 10.1159/000449346
M3 - Article
SN - 2235-1795
VL - 6
SP - 34
EP - 43
JO - Liver Cancer
JF - Liver Cancer
IS - 1
ER -